A single-cell analysis of nearly 18,000 white blood cells identifies a unique neutrophil subset characterized by type II ...

Prophylactic trimethoprim-sulfamethoxazole lowered serious infection risk in patients with ANCA-associated vasculitis, ...

The global market for ANCA-associated vasculitis (ANCA-V) treatments has been expanding steadily, driven by advancements in treatment options, growing disease awareness, and the development of ...

VEXAS syndrome is known to be a mimicker of ANCA-associated vasculitis, making it a challenge to distinguish between the disorders. VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory ...

Researchers from The University of Osaka discover that specific white blood cells and the amount of an inflammation protein ...

Early glucocorticoid withdrawal is feasible and was well tolerated in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis ... that induction treatment with combination ...

Vaccines and ongoing vigilance are critical to prevent and manage infections in patients who are immunosuppressed or ...

CLEVELAND, May 19, 2025 (GLOBE NEWSWIRE) -- NovelMed is pleased to announce positive 12-week interim results from the ongoing ...

Sana Biotechnology, Inc.’s SANA share price has dipped by 5.61%, which has investors questioning if this is right time to buy ...

General and administrative (G&A) expenses were $12.4 million for the first quarter of 2025, which included $5.1 million of restructuring expenses in March 2025. Non-cash stock-based compensation ...

“ANCA-associated vasculitis affects the smallest blood vessels ... patients with vasculitis had very high mortality because we knew only the disease, but not the treatment. Once the global idea of ...